(R*,S*)-(-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone

Absorption

Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.

Toxicity

Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor.

Description

Like pirbuterol, procaterol exhibits similar broncholytic properties as albuteral, but it has somewhat of a more prolonged action. It is recommended for use as an inhaled drug for treating bronchial asthma.

Chemical properties

Off-White Solid

The Uses of (R*,S*)-(-)-8-Hydroxy-5-(1-hydroxy-2-((1-methylethyl)amino)butyl)-2(1H)-quinolinone

A labelled intermediate of the enantiomer of Florfenicol (F405750), an antibacterial agent.

Indications

For the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Background

A long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

Definition

ChEBI: 8-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)butyl]-1H-quinolin-2-one is a member of quinolines.

brand name

Pro-Air (Parke-Davis).

Pharmacokinetics

Procaterol is a long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

Synthesis

Procaterol, 5-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-8-hydroxy-2-(1H) quinolone (23.3.25), is synthesized by acylation of 8-hydroxy-2(1H)-quinolone with 2-bromobutyric acid chloride at the fifth position of the quinoline system, which gives the compound 23.3.23. This undergoes action of isopropylamine, forming an aminoketone 23.3.24, the carbonyl group of which is reduced by sodium borohydride, giving procaterol (23.3.25) .

Metabolism

Not Available